MicroPulse® Laser Trabeculoplasty (MLT)

“MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications.”

Iqbal (Ike) Ahmed, MD, FRCSC
University of Toronto

“MLT is versatile in a variety of ways: for patients just starting therapy, replacing an eye drop, as an adjunct to an eye drop or to keep them away from incisional surgery.”

Nathan Radcliffe, MD
New York Eye Surgery Center

Long-Term Multi-Center Data using 1000 mW

Pre-op ≥ 21 mmHg

<table>
<thead>
<tr>
<th>IOP mm Hg</th>
<th>Baseline</th>
<th>1 month</th>
<th>3-4 months</th>
<th>6 months</th>
<th>1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>24.4 ± 3.6</td>
<td>24.6%</td>
<td>28.3%</td>
<td>28.3%</td>
<td>24.2%</td>
<td></td>
</tr>
<tr>
<td>18.4 ± 2.9</td>
<td>17.5 ± 2.9</td>
<td>17.5 ± 3.6</td>
<td>18.5 ± 0.9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The 1 year results show approximately 6 mm Hg drop in IOP equating to a 25% reduction.

One Year IOP Results

# of pts 40 34 34 13 10

Evidence of Dose Response

The data shows the greatest IOP reduction was experienced by performing MLT at 1000 mW.

![Graph showing % IOP Reduction at different power levels: 300mW, 700mW, 1000mW for 1 Month, 4 Months, 12 months.](image)

David Gossage, DO, FAOCO, FAAO, Gossage Eye Institute, Hillsdale, MI

MLT Lens

- Rotatable indexing ring allows for confluent laser treatment without removing the MLT lens from the eye
- Tactile positions of the indexing ring are aligned to clock hours, thus facilitating memory of approximate location of previous subthreshold laser spots in the case the patient blinks
- Visible white reference guide assists placement of 10 confluent laser treatments per clock hour

Emergo Europe
Molenstraat 15, 2513 BH, The Hague, The Netherlands, Tel.: (31) (0) 70 345-8570, Fax: (31) (0) 70 346-7299

©2014 IRIDEX. Printed in U.S.A. L70609 10/2014

Specifications are subject to change without notice. IRIDEX, IRIDEX logo and MicroPulse are registered trademarks and TxCell and IQ 532 are trademarks of IRIDEX Corporation. All other trademarks are the property of their respective owners.

Products are covered by one or more of the following U.S. patents: 5,511,085; 5,982,789; 6,237,291; 6,540,291; 6,733,490; 7,766,904; 7,771,417; 7,909,816; 5,997,498; 6,073,759; 6,092,898; 6,217,594; 6,494,314; 6,585,679; 6,726,066; 6,800,076; 6,866,142; 7,537,593; 8,177,777; 783783; 69530497.6; KR 348012; 0904615; 69706541.3; CA 2331837; AU 759193; JP 4149670; EP 1009684; CA 2286002; JP 449444; JP 4570696; JP 4819754; JP 5123973; JP 5133069.

Other U.S. and international patents pending.